復星醫藥(600196.SH):子公司與雅各臣就mRNA新冠疫苗於香港、澳門的供應及分銷合作達成意向
格隆匯 8 月 27日丨復星醫藥(600196.SH)公佈,2020年8月27日,公司控股子公司復星實業(香港)有限公司(“復星實業”)與Jacobson Pharma Corporation Limited(即雅各臣科研製藥有限公司,“雅各臣”)簽訂《Letter of Intent》(“意向書”),雙方(即復星實業、雅各臣)就mRNA新冠疫苗於合作區域(即中國香港特別行政區、澳門特別行政區,下同)的供應及分銷合作達成意向。
意向書的主要內容:1、復星實業、雅各臣就mRNA新冠疫苗在合作區域的供應及分銷合作達成意向。擬由復星實業(基於復星醫藥產業再許可而獲得的於合作區域就mRNA新冠疫苗的商業化權利)向雅各臣供應、並由雅各臣在合作區域經銷1000萬劑mRNA新冠疫苗,具體分銷合作條款待進一步商議。
2、意向書將於下述情況發生時終止(孰早):(1)意向書簽訂後的4個月,(2)復星實業書面通知雅各臣終止意向書。
3、意向書適用中國香港特別行政區法律;意向書項下爭議無法協商解決的,應提交香港國際仲裁中心仲裁,並依據該仲裁機構屆時有效的仲裁規則進行仲裁。
4、意向書系雙方合作的意向性文件,除保密、法律適用、爭議解決等條款外,意向書未就本次合作創設其他約束性權利義務。
5、意向書自雙方簽署後生效。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.